Physician profile
Randy C Randall
NPI 1003847716
$563.38
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $78.84 · 2021: $110 · 2022: $49.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $182.06 | 2019-2022 | |
| Amgen INC. | $117.79 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $81.58 | 2019-2021 | |
| Lundbeck LLC | $52.81 | 2019 | |
| Gilead Sciences, INC. | $46.80 | 2019 | |
| Pfizer INC. | $28.76 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.90 | 2019 | |
| Astellas Pharma US INC | $13.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.